Pipkorn U
Eur J Respir Dis Suppl. 1982;122:185-91.
In a nasal allergen challenge test, the effect of the glucocorticosteroid budesonide on the pollen allergic type I reaction was investigated. Placebo and two different doses of budesonide were given intranasally for one week before the challenge. The study was designed as a double-blind cross-over trial. Treatment for one week with the active steroid significantly reduced the nasal secretion compared with placebo, as measured with the aid of a symptom score, and significantly reduced the induced nasal blockage measured objectively by rhinomanometry. No difference was found between the two doses of budesonide, 400 micrograms and 100 micrograms daily, used in the study.
在一项鼻过敏原激发试验中,研究了糖皮质激素布地奈德对花粉过敏性I型反应的影响。在激发试验前一周,经鼻给予安慰剂和两种不同剂量的布地奈德,为期一周。该研究设计为双盲交叉试验。与安慰剂相比,使用活性类固醇治疗一周后,根据症状评分测量,鼻分泌物显著减少,并且通过鼻阻力计客观测量的诱导性鼻阻塞也显著降低。在该研究中使用的每日400微克和100微克这两种布地奈德剂量之间未发现差异。